Back to News
Market Impact: 0.25

Planet Labs vs. Snowflake: Evaluating the Better High-Growth Stock to Buy for 2026

Source: The Motley Fool

Technology & InnovationArtificial IntelligenceCorporate EarningsCompany FundamentalsAnalyst EstimatesCredit & Bond Markets

Planet Labs reported record FY2Q revenue of $116.1M, up 58% YoY, with 52-week-high momentum for Snowflake alongside its FY2Q revenue of $1.6B (+35% YoY). Despite strong top-line growth, both remain loss-making (Planet Labs net loss of $246.9M; Snowflake net loss of $1.3B), with heavily negative margins and SBC-driven cash generation distortion. Valuation shows Planet Labs at a lower P/S (18.3x vs. 21.7x for Snowflake), while Snowflake’s recent AI-driven adoption is cited as the longer-term growth edge—yet the article ultimately favors buying Planet Labs based on valuation and sales momentum.

Analysis

SNOW is the higher-quality business, but its valuation already assumes AI consumption stays resilient through the next several quarters. The key mechanism is that consumption-based revenue gives upside in expansions and downside in budget normalization; at this multiple, the market is paying for a smooth growth path that enterprise spend rarely delivers. PL is the opposite: cheaper on sales, but the real question is not growth, it is whether the growth base is broad enough to offset launch risk, dilution, and customer concentration.

The second-order winners are the hyperscalers and adjacent data tooling vendors, not just the two names here. AMZN and MSFT benefit if AI workloads keep expanding, but they also have the leverage to bundle against SNOW and compress pricing over time; that makes SNOW less of a pure AI beta than investors think. For PL, defense and insurance use cases can create sticky demand, but procurement cycles are lumpy, so upside likely comes in bursts rather than a clean compounding story.

Near term, the stock reaction should be driven by guidance and retention metrics over the next 1-3 months, while the structural debate plays out over 6-18 months. The contrarian read is that PL's cheapness is partly optical because SBC and leverage can convert equity upside into dilution, while SNOW's richness is partly justified if cash margins keep improving. What would falsify the SNOW-over-PL quality thesis is a consumption growth deceleration or broad SaaS multiple compression; what would falsify the PL bear case is evidence of diversified recurring demand and a sustained margin inflection.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

-0.05

Ticker Sentiment

PL0.35
SNOW0.20

Key Decisions for Investors

  • Relative-value: go long SNOW / short PL for 1-3 months into the next earnings cycle. Thesis is quality and revenue durability versus balance-sheet and concentration risk; target 10-15% spread, stop if PL lands a materially new government/customer win or SNOW guides consumption growth materially below trend.
  • Do not chase PL at current levels; treat it as a watchlist name until there is proof of broader customer diversification and lower SBC dilution. If those metrics do not improve in the next 1-2 quarters, keep it off the buy list.
  • Prefer AMZN or MSFT over SNOW for lower-risk AI/cloud exposure if the goal is participation in data growth without paying a premium pure-play multiple. Use SNOW only if you want higher beta to enterprise AI usage and can tolerate multiple compression risk.
  • Set an alert on SNOW if forward revenue growth starts to decelerate faster than the market expects; that is the cleanest catalyst for multiple compression. Conversely, if PL begins to show consistent margin improvement and lower net loss severity over 2-3 quarters, reassess the short leg.
  • For cautious capital, wait for a pullback in SNOW rather than buying momentum at a high multiple; the better entry is usually after an 'in-line' print, not after a breakout.

More News

From AllMind Research

Browse all research